Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
Laura MansiElsa Kalbacher

Abstract

The goal of this study was to determine the benefit in terms of time disease control (TDC) achieved by the succession of chemotherapy beyond the third line in patients treated for recurrent epithelial ovarian cancer. Secondary objectives were to identify patients who benefited from treatments beyond 3 lines and to estimate overall survival and disease-free progression lengths. The cohort of 122 patients was identified from a pharmacy database of patients treated with chemotherapy between 1992 and 2010. The evaluation of benefit obtained by each line was based on TDC duration, defined as the interval between the beginning of the treatment and the date of progressive disease or death. Median TDC durations was 4.15 (0-54.7), 4 (0-21.7), 3.34 (0-29.6), 4.97 (0-29.2), and 3.13 months (0-15) for the fourth to eighth lines, respectively. Time to disease control was longer than 6 months in 34% to 40% of patients treated by lines 4 to 8. The most important factor influencing TDC length beyond the third line was the TDC duration observed in the 2 previous lines of therapy. Median overall survival after the third line was 15.3 months (95% confidence interval, 12-20 months). Factors associated with longer overall survival after 3 lines wer...Continue Reading

References

Mar 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MarkmanJ L Lewis
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W ten Bokkel HuininkJ F Heron
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P NeijtH C van Houwelingen
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonT Sharpington
Jul 30, 2002·Gynecologic Oncology·Kristine A DonovanDiane C Tucker
Dec 31, 2002·Gynecologic Oncology·Laura J HavrileskyMichael E Carney
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group
Sep 4, 2003·Journal of the National Cancer Institute·Andreas du BoisUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·M J PiccartW McGuire
Aug 19, 2005·Journal de gynécologie, obstétrique et biologie de la reproduction·B TrétarreJ P Daurès
Aug 23, 2005·Gynecologic Oncology·Nobuhiro TakeshimaKatsuhiko Hasumi
Sep 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacobus PfistererUNKNOWN EORTC GCG
Dec 13, 2006·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·A P M HeintzU Beller
Mar 24, 2007·Breast Cancer Research and Treatment·Armelle DufresneAimery De Gramont
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jalid SehouliWerner Lichtenegger
Oct 2, 2009·Lancet·Bryan T HennessyMaurie Markman
May 7, 2010·Journal of the National Cancer Institute·Baptist TrimbosAntonio Casado
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineAndreas du Bois
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkAndrés M Poveda
Dec 24, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Richard Wyn GriffithsJurjees Hasan
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandro PignataFrancesco Perrone
Aug 23, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L C HankerUNKNOWN AGO and GINECO study group
Dec 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A González-Martín
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard
Nov 1, 2006·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Apm HeintzU Beller

❮ Previous
Next ❯

Citations

May 1, 2016·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.